JP2021075580A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021075580A5 JP2021075580A5 JP2021025286A JP2021025286A JP2021075580A5 JP 2021075580 A5 JP2021075580 A5 JP 2021075580A5 JP 2021025286 A JP2021025286 A JP 2021025286A JP 2021025286 A JP2021025286 A JP 2021025286A JP 2021075580 A5 JP2021075580 A5 JP 2021075580A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- specifically binds
- arm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 239
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 97
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 97
- 239000003795 chemical substances by application Substances 0.000 claims 47
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 18
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 14
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 13
- 239000004220 glutamic acid Substances 0.000 claims 12
- 230000001629 suppression Effects 0.000 claims 12
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 11
- 235000013922 glutamic acid Nutrition 0.000 claims 11
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 10
- 208000023275 Autoimmune disease Diseases 0.000 claims 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 9
- 235000003704 aspartic acid Nutrition 0.000 claims 9
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 9
- 235000018977 lysine Nutrition 0.000 claims 9
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 8
- 239000004472 Lysine Substances 0.000 claims 8
- 239000004480 active ingredient Substances 0.000 claims 8
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 7
- 235000001014 amino acid Nutrition 0.000 claims 7
- 208000024908 graft versus host disease Diseases 0.000 claims 7
- 208000024891 symptom Diseases 0.000 claims 7
- 239000004475 Arginine Substances 0.000 claims 6
- 229940024606 amino acid Drugs 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 6
- 235000009697 arginine Nutrition 0.000 claims 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229930182817 methionine Natural products 0.000 claims 5
- 235000013930 proline Nutrition 0.000 claims 5
- 206010069754 Acquired gene mutation Diseases 0.000 claims 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
- 239000004471 Glycine Substances 0.000 claims 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Chemical group CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 4
- 239000004473 Threonine Chemical group 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 235000009582 asparagine Nutrition 0.000 claims 4
- 229960001230 asparagine Drugs 0.000 claims 4
- 210000004602 germ cell Anatomy 0.000 claims 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 4
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 4
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 230000037439 somatic mutation Effects 0.000 claims 4
- 102000009109 Fc receptors Human genes 0.000 claims 3
- 108010087819 Fc receptors Proteins 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims 2
- 101000989065 Homo sapiens Immunoglobulin heavy variable 7-4-1 Proteins 0.000 claims 2
- 102100029420 Immunoglobulin heavy variable 7-4-1 Human genes 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 102100037850 Interferon gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 101150008942 J gene Proteins 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 2
- 206010034277 Pemphigoid Diseases 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 101150117115 V gene Proteins 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 2
- 230000016396 cytokine production Effects 0.000 claims 2
- 230000002327 eosinophilic effect Effects 0.000 claims 2
- 230000003993 interaction Effects 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 206010048628 rheumatoid vasculitis Diseases 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 206010002065 Anaemia megaloblastic Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000005024 Castleman disease Diseases 0.000 claims 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000010007 Cogan syndrome Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 claims 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 1
- 206010016228 Fasciitis Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000008899 Habitual abortion Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 206010019939 Herpes gestationis Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000021330 IgG4-related disease Diseases 0.000 claims 1
- 208000037142 IgG4-related systemic disease Diseases 0.000 claims 1
- 208000004187 Immunoglobulin G4-Related Disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 claims 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 claims 1
- 208000001244 Linear IgA Bullous Dermatosis Diseases 0.000 claims 1
- 208000012309 Linear IgA disease Diseases 0.000 claims 1
- 208000000185 Localized scleroderma Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010061323 Optic neuropathy Diseases 0.000 claims 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 206010036697 Primary hypothyroidism Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 206010062164 Seronegative arthritis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000008736 Systemic mastocytosis Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010052568 Urticaria chronic Diseases 0.000 claims 1
- 208000025749 Vogt-Koyanagi-Harada disease Diseases 0.000 claims 1
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 claims 1
- 229960003697 abatacept Drugs 0.000 claims 1
- 210000004100 adrenal gland Anatomy 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000003092 anti-cytokine Effects 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 206010003883 azoospermia Diseases 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims 1
- 208000024376 chronic urticaria Diseases 0.000 claims 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 230000006589 gland dysfunction Effects 0.000 claims 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 claims 1
- 208000003532 hypothyroidism Diseases 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 231100001016 megaloblastic anemia Toxicity 0.000 claims 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000008795 neuromyelitis optica Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 208000020911 optic nerve disease Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 208000034213 recurrent susceptibility to 1 pregnancy loss Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 201000005671 spondyloarthropathy Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019139751 | 2019-07-30 | ||
| JP2019139751 | 2019-07-30 | ||
| JP2020570992A JP6856183B1 (ja) | 2019-07-30 | 2020-07-29 | 二重特異性抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570992A Division JP6856183B1 (ja) | 2019-07-30 | 2020-07-29 | 二重特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021075580A JP2021075580A (ja) | 2021-05-20 |
| JP2021075580A5 true JP2021075580A5 (enExample) | 2023-07-06 |
| JP7574692B2 JP7574692B2 (ja) | 2024-10-29 |
Family
ID=74229916
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570992A Active JP6856183B1 (ja) | 2019-07-30 | 2020-07-29 | 二重特異性抗体 |
| JP2021025286A Active JP7574692B2 (ja) | 2019-07-30 | 2021-02-19 | 二重特異性抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570992A Active JP6856183B1 (ja) | 2019-07-30 | 2020-07-29 | 二重特異性抗体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220281977A1 (enExample) |
| EP (1) | EP4008348A4 (enExample) |
| JP (2) | JP6856183B1 (enExample) |
| KR (1) | KR20220039720A (enExample) |
| CN (1) | CN114174343A (enExample) |
| AU (1) | AU2020322765A1 (enExample) |
| BR (1) | BR112022001473A2 (enExample) |
| CA (1) | CA3149309A1 (enExample) |
| IL (1) | IL290050A (enExample) |
| MX (1) | MX2022000971A (enExample) |
| PH (1) | PH12022550190A1 (enExample) |
| TW (1) | TW202118790A (enExample) |
| WO (1) | WO2021020416A1 (enExample) |
| ZA (1) | ZA202201247B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI804572B (zh) * | 2018-02-09 | 2023-06-11 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
| CN120752054A (zh) | 2023-03-16 | 2025-10-03 | 小野药品工业株式会社 | 抗体制剂 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
| FI884924L (fi) | 1987-10-28 | 1989-04-29 | Oncogen | Humanimmuglobulin som producerats med hybrid-dna-teknik. |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5151504A (en) | 1989-11-17 | 1992-09-29 | E. R. Squibb & Sons, Inc. | Method for purification of monoclonal antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| ATE243747T1 (de) | 1991-07-15 | 2003-07-15 | Wellcome Found | Herstellung von antikörpern |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| ATE289354T1 (de) | 1999-04-15 | 2005-03-15 | Crucell Holland Bv | Verwendung von adenovirus e1 protein sequenzen kodierenden, zur herstellung von rekombinanten proteinen in menschlichen zellen. |
| DK1354034T3 (da) | 2000-11-30 | 2008-03-25 | Medarex Inc | Transgene transchromosomale gnavere til fremstilling af humane antistoffer |
| NZ519012A (en) | 2001-05-21 | 2003-10-31 | Orgapack Gmbh | Manually actuated strapping unit for wrapping a steel strap around a packaged item |
| US20040241745A1 (en) | 2001-07-31 | 2004-12-02 | Tasuku Honjo | Substance specific to pd-1 |
| SI1523496T1 (sl) | 2002-07-18 | 2011-11-30 | Merus B V | Rekombinantno proizvajanje zmesi protiteles |
| JP2004072286A (ja) | 2002-08-05 | 2004-03-04 | Nippon Telegr & Teleph Corp <Ntt> | 構造変化検出方法および通信網異常状態検出方法、並びに、その装置およびプログラム |
| EP1591527B1 (en) * | 2003-01-23 | 2015-08-26 | Ono Pharmaceutical Co., Ltd. | Substance specific to human pd-1 |
| CA2545603A1 (en) * | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
| ES2526343T3 (es) | 2004-06-03 | 2015-01-09 | Novimmune Sa | Anticuerpos anti-CD3 y métodos de uso de los mismos |
| BRPI0517837A (pt) * | 2004-11-12 | 2008-10-21 | Xencor Inc | variantes fc com ligação alterada a fcrn |
| RU2559524C2 (ru) * | 2008-06-27 | 2015-08-10 | Мерюс Б.В. | Продуцирующие антитела млекопитающие, не являющиеся человеком |
| WO2013022091A1 (ja) | 2011-08-11 | 2013-02-14 | 小野薬品工業株式会社 | Ｐｄ－１アゴニストからなる自己免疫疾患治療剤 |
| ES2743399T3 (es) | 2012-04-20 | 2020-02-19 | Merus Nv | Métodos y medios para la producción de moléculas heterodiméricas similares a Ig |
| US10358492B2 (en) | 2012-09-27 | 2019-07-23 | Merus N.V. | Bispecific IgG antibodies as T cell engagers |
| EP3345928B1 (en) * | 2015-07-10 | 2020-06-24 | Merus N.V. | Human cd3 binding antibody |
| EP3353210B8 (en) * | 2015-09-25 | 2024-12-18 | F. Hoffmann-La Roche AG | Anti-tigit antibodies and methods of use |
| MX2019014577A (es) * | 2017-06-05 | 2020-07-29 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y metodos de uso. |
| TW201930351A (zh) * | 2017-10-06 | 2019-08-01 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
| TWI804572B (zh) * | 2018-02-09 | 2023-06-11 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
-
2020
- 2020-07-29 BR BR112022001473A patent/BR112022001473A2/pt not_active IP Right Cessation
- 2020-07-29 CA CA3149309A patent/CA3149309A1/en active Pending
- 2020-07-29 US US17/630,426 patent/US20220281977A1/en active Pending
- 2020-07-29 CN CN202080054077.0A patent/CN114174343A/zh active Pending
- 2020-07-29 WO PCT/JP2020/028972 patent/WO2021020416A1/ja not_active Ceased
- 2020-07-29 AU AU2020322765A patent/AU2020322765A1/en not_active Abandoned
- 2020-07-29 MX MX2022000971A patent/MX2022000971A/es unknown
- 2020-07-29 KR KR1020227003026A patent/KR20220039720A/ko not_active Abandoned
- 2020-07-29 PH PH1/2022/550190A patent/PH12022550190A1/en unknown
- 2020-07-29 TW TW109125604A patent/TW202118790A/zh unknown
- 2020-07-29 JP JP2020570992A patent/JP6856183B1/ja active Active
- 2020-07-29 EP EP20846826.4A patent/EP4008348A4/en active Pending
-
2021
- 2021-02-19 JP JP2021025286A patent/JP7574692B2/ja active Active
-
2022
- 2022-01-23 IL IL290050A patent/IL290050A/en unknown
- 2022-01-26 ZA ZA2022/01247A patent/ZA202201247B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011237679B2 (en) | TNF-alpha binding proteins | |
| JP6844719B2 (ja) | 二重特異性抗体 | |
| JP2020509756A5 (enExample) | ||
| US20130108641A1 (en) | Anti-gitr antibodies | |
| JP7688805B2 (ja) | 二重特異性抗体 | |
| CN114286827A (zh) | 人源化抗il17a抗体及其应用 | |
| JP2012514458A (ja) | 抗リンホトキシン抗体 | |
| JP2021075580A5 (enExample) | ||
| AU2015200579A1 (en) | TNF-alpha binding proteins | |
| JP2019518473A5 (enExample) | ||
| JP7574692B2 (ja) | 二重特異性抗体 | |
| JP7714992B2 (ja) | 二重特異性抗体を有効成分として含む医薬組成物 | |
| JP2022060182A5 (enExample) | ||
| RU2814713C2 (ru) | Биспецифическое антитело | |
| RU2814713C9 (ru) | Биспецифическое антитело | |
| JP2019103502A (ja) | Ｉｌ−１１ｒ結合タンパク質及びその使用 | |
| RU2021128262A (ru) | Биспецифическое антитело | |
| HK40062297A (en) | Bispecific antibody | |
| HK40062297B (zh) | 双特异性抗体 | |
| HK40036202A (en) | Bispecific antibody | |
| NZ761547B2 (en) | Bispecific antibody | |
| HK40036202B (zh) | 双特异性抗体 |